Cross-source identity
National Provider Identifier 1023404613 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|
| CMS NPPES | NPI 1023404613 | Registry identity — psychiatrist, taxonomy 2084P0800X | Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Open Payments | NPI 1023404613 | 257 industry-payment records, 2024 | Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1023404613 | 37 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity 1ea3934e… | Canonical resolved node · 2 identifier(s) · 9 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $4,585 | 257 |
| Manufacturer | Amount | Records |
|---|---|---|
| Abbvie Inc. | $496 | 33 |
| Pfizer Inc. | $373 | 25 |
| Lilly Usa, Llc | $370 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Dimethyl Fumarate | 14 | $120,957 |
| Nurtec Odt(Rimegepant Sulfate) | 35 | $47,096 |
| Ubrelvy(Ubrogepant) | 18 | $19,977 |
| Emgality Pen(Galcanezumab-Gnlm) | 16 | $16,401 |
| Lyrica(Pregabalin) | 13 | $14,660 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| Relationship | Entity | Source |
|---|---|---|
| ← pays | Novartis Pharmaceuticals Corporation (NJ) | cms_open_payments |
| ← pays | Ani Pharmaceuticals, Inc. (MN) | cms_open_payments |
| ← pays | Boston Scientific Corporation (MA) | cms_open_payments |
| ← pays | Alexion Pharmaceuticals, Inc. (MA) | cms_open_payments |
| ← pays | Celgene Corporation (NJ) | cms_open_payments |
| ← pays | Abbvie Inc. (IL) | cms_open_payments |
| ← pays | Biogen, Inc. (MA) | cms_open_payments |
| ← pays | Eisai Inc. (NJ) | cms_open_payments |
| ← pays | Amgen Inc. (CA) | cms_open_payments |
| 25 |
| Novartis Pharmaceuticals Corporation | $354 | 33 |
| Ucb, Inc. | $281 | 16 |